Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $240.0 million.

  • Assembly Biosciences' Liabilities and Shareholders Equity rose 13936.99% to $240.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 1411.65%. This contributed to the annual value of $119.2 million for FY2024, which is 1290.35% down from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Liabilities and Shareholders Equity is $240.0 million, which was up 13936.99% from $80.8 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Liabilities and Shareholders Equity registered a high of $278.9 million during Q1 2021, and its lowest value of $51.6 million during Q3 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $119.9 million (2024), whereas its average is $143.3 million.
  • In the last 5 years, Assembly Biosciences' Liabilities and Shareholders Equity plummeted by 5751.26% in 2023 and then surged by 13936.99% in 2025.
  • Quarter analysis of 5 years shows Assembly Biosciences' Liabilities and Shareholders Equity stood at $191.1 million in 2021, then plummeted by 46.72% to $101.8 million in 2022, then surged by 34.41% to $136.8 million in 2023, then dropped by 12.9% to $119.2 million in 2024, then skyrocketed by 101.39% to $240.0 million in 2025.
  • Its last three reported values are $240.0 million in Q3 2025, $80.8 million for Q2 2025, and $99.0 million during Q1 2025.